331 results on '"Topp, M"'
Search Results
2. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.
3. NLO Monte Carlo predictions for heavy-quark production at the LHC: pp collisions in ALICE
4. Axicabtagene ciloleucel (Axicel) for relapsed/refractory primary mediastinal B‐cell lymphoma (r/r PMBCL) compared to DLBCL‐NOS: A GLA/DRST registry study.
5. 3‐Year outcomes of adults with relapsed or refractory B‐cell acute lymphoblastic leukemia treated with brexu‐cel in ZUMA‐3 by age, prior therapies, and subsequent transplant
6. Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non‐Hodgkin lymphoma (R/R NHL): update of a Phase Ib study
7. Neue Entwicklungen in der Therapie des fortgeschrittenen klassischen Hodgkin-Lymphoms
8. CXCR4-gerichtete PET/CT in 100 Patient:innen mit Marginalzonenlymphom -Diagnostische Performance, Vorhersagepotenzial und Eignung für CXCR4-Endoradiotherapie
9. Einfluss einer erhöhten Manifestations-Last auf die Ga-68-PentixaFor Biodistribution bei Patient:innen mit Marginalzonenlymphom - Potentielle therapeutische Implikationen
10. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
11. P356: SUBGROUP ANALYSES OF KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN ZUMA-3
12. Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
13. Management of Adults and Children receiving CAR T-cell therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
14. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
15. Application of T Cell lmmunotherapy for Human Viral and Malignant Diseases
16. Management of adults and children receiving CAR T- cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
17. Fast relaxation processes in jet-cooled van der Waals clusters involving large aromatic molecules
18. Nanosecond Flash Photolysis
19. CLINICAL RESPONSES TO ODRONEXTAMAB (REGN1979): CORRELATION WITH LOSS OF CD20 EXPRESSION AS A POTENTIAL MECHANISM OF RESISTANCE AND BASELINE BIOMARKERS OF TUMOR T CELLS
20. OUTCOME DETERMINANTS OF COMMERCIAL CAR‐T CELL THERAPY FOR LARGE B‐CELL LYMPHOMA: RESULTS OF THE GLA/DRST REAL WORLD ANALYSIS
21. 52-jähriger Patient mit schwerer Herzinsuffizienz bei multiplem Myelom
22. Dose-Intensification in early unfavorable Hodgkin Lymphoma: Long-Term Follow up of the randomized German Hodgkin Study Group (GHSG) HD14 trial
23. Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin Lymphoma: Final results of the international, randomized Phase III HD17 trial by the German Hodgkin Study Group
24. ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer
25. Case gender and severity in cerebral palsy varies with intrauterine growth
26. Anti-CD19 BiTE® blinatumomab induces high complete remission rates in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukaemia (ALL) including relapse after stem cell transplantation (SCT): O314
27. Auto-SCT in severe paraproteinemic neuropathy
28. Targeting heat shock protein 90 and Akt synergistically suppresses essential immune functions of alloreactive T cells: V726
29. Characterization of human Aspergillus fumigatus-specific regulatory T cells: V657
30. Blinatumomab (CD3/CD19 Bite® Antibody) results in a high response rate in patients with relapsed non-hodgkin lymphoma (NHL) including mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL): V646
31. Clinical activity of the anti-CD19 bite® blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL): Interim results of a phase II study: V104
32. Allogeneic stem cell transplantation for Hodgkinʼs disease: a retrospective analysis of data from the German stem cell transplantation registry (DRST) and GCTSG: P852
33. Aspergillus fumigatus and Candida albicans shared T-cells epitopes drive the immune response in healthy individuals: V983
34. Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin Lymphoma: Results of the second interim analysis of the GHSG HD13 trial: V448
35. Blinatumomab (Anti-CD19 BiTE®) for targeted therapy of minimal residual disease (MRD) in patients with B precursor acute lymphoblastic leukemia (ALL): Update of an ongoing phase II study: V341
36. Treatment with 2 cycles of BEACOPPesc followed by 2 cycles of ABVD and IF-RT is superior to 4 cycles of ABVD and IF-RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 trial: V336
37. Clinical activity of PAT-SM6 monoclonal antibody in advanced and extramedullary Multiple Myeloma: results from a phase I study and a single patient treatment use
38. Interim results of a multicenter, single-arm study to assess Blinatumomab in adult patients (pts) with minimal residual disease (MRD) of B-precursor (BCP) acute lymphoblastic leukemia (GMALL-MOLACT1-BLINA)
39. Pet positivity after 2 cycles of abvd is a risk factor in patients with early-stage favorable Hodgkin lymphoma treated in the phase 3 GHSG HD16 study
40. Supertough poly(lactide)s
41. Efficient Lyse of Hodgkin Cells by LMP2a-Specific CD8+ T-Cells but not by LMP-1 Specific CD8+ T-Cells. Implication for Design of Adoptive Immunotherapy in HD-Patients after Allogeneic SCT: O295
42. LMP-2a but not LMP-1 specific CD8+ T-cells can lyse efficiently NHL-lymphoma cells. Implication for the design of adoptive immunotherapy of relapsed EBV+ lymphomas after allogeneic SCT
43. Specific lysis of multiple myeloma cells by T cells engineered to express a chimeric immune receptor targeting HM 1.24: V314
44. Definition of a previously unknown HCMV IE1 peptide motif by computer-based epitope prediction: 705
45. PS1240 EVEROLIMUS WITH DHAP (DEXAMETHASONE, HIGH-DOSE ARAC, CISPLATINUM) IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A RANDOMIZED, PLACEBO-CONTROLLED PHASE I/II TRIAL (HD-R3I)
46. S825 EVALUATION OF AMG 420, AN ANTI‐BCMA BISPECIFIC T‐CELL ENGAGER (BITE®) IMMUNOTHERAPY, IN R/R MULTIPLE MYELOMA (MM) PATIENTS: UPDATED RESULTS OF A FIRST‐IN‐HUMAN (FIH) PHASE 1 DOSE ESCALATION STUDY
47. PB1780 TREATMENT OF R/R BURKITT LYMPHOMA WITH BLINATUMOMAB IS FEASIBLE AND INDUCED A LONG LASTING COMPLETE REMISSION
48. Megakaryocyte Growth and Development Factor Does Not Stimulate Growth of Lymphomas and Solid Tumors in vitro
49. The Sensitivity of Rapid Tests for SARS-CoV-2 Antigen: Association With Clinical Manifestations, Viral Load, and Sublines: Association with clinical manifestations, viral load, and sublines.
50. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.